EUR/USD likely to find a peak near 1.25: UBS
NEW YORK - Enovis Corporation (NYSE:ENOV) reported first-quarter results that fell short of analyst expectations on the top line, while providing full-year guidance below consensus on Thursday.
The company’s shares were down 4.94% % in pre-marketmarket trading following the release.
The medical technology company posted adjusted earnings per share of $0.81, beating the analyst estimate of $0.74. However, revenue of $558.83 million narrowly missed the consensus forecast of $558.9 million.
For the first quarter, Enovis saw sales grow 8.2% YoY on a reported basis and 9.3% on a comparable basis. The Reconstructive segment led growth, with sales up 11.3% to $286.3 million. Prevention & Recovery segment sales increased 5.2% to $272.6 million.
"We delivered a strong start to 2025, with first-quarter revenues and margins exceeding expectations," said Matt Trerotola, Chief Executive Officer of Enovis. "This performance reflects the strength of our business system and the discipline of our teams as we navigate a complex global environment."
Looking ahead, Enovis updated its full-year 2025 outlook, now expecting revenue between $2.22-2.25 billion, up from its prior range of $2.19-2.22 billion but still below the analyst consensus of $2.21 billion at the midpoint. The company lowered its adjusted EPS guidance to $2.95-$3.10, down from $3.10-$3.25 previously and below the $3.18 consensus estimate.
The reduced earnings outlook includes a $20 million impact from tariffs. Enovis also trimmed its adjusted EBITDA forecast to $385-395 million from $405-415 million previously.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.